Biocon Ltd News

Stocks to Watch today: Rate sensitives, Infosys, Aurobindo Pharma, GAIL

Stocks to Watch today, April 8, 2026: Banks, Real estate, automobiles, Infosys, Aurobindo Pharma are some of the key stocks to watch today

Biocon shares slip 4% amid heavy volumes; 9.58 mn shares traded on NSE

According to Bloomberg, 3.19 million shares were traded in multiple block deals. Buyers and sellers of the transactions were not known

Biocon seeks to be the top global insulin player as rivals turn to GLP-1

Company plans to leverage capacity gaps and pricing dynamics in insulin as global pharma majors shift focus to GLP-1 therapies amid rising diabetes burden

Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

Nifty Pharma index falls for 4th day, sinks 4% as new US tariff risks mount

Nifty Pharma index today: The Trump administration may announce new tariffs on drugmakers that have not struck deals guaranteeing low prices in the country

We've always been an India player, says Biocon MD Shreehas Tambe

Biocon Limited names Shreehas Tambe CEO, outlines AI-led, integration-driven strategy to boost global biosimilars and generics growth

Biocon appoints Shreehas Tambe as CEO & MD effective from April 1

Biocon Ltd on Friday said it has appointed Shreehas Tambe as CEO & Managing Director, effective April 1, 2026. As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the company's ability to operate at scale and compete effectively in global markets, the company said in a statement. Further, Kedar Upadhye has also been appointed as Chief Financial Officer, Biocon said. This leadership transition is part of the full integration of Biocon Biologics Ltd as a wholly-owned subsidiary of Biocon Ltd, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies, the company said. Commenting on the development, Biocon Ltd Executive Chairperson, Kiran Mazumdar-Shaw said the company has consistently grown by .

Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.

Nifty Pharma eyes breakout; Biocon, 2 others may rally up to 22%: Analyst

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Biopharma Shakti shows India focusing on being biopharma hub: Biocon's Shaw

After cutting debt and raising $1 billion, Biocon sharpens its biosimilars and GLP-1 play, betting on scale, regulatory reform and AI to power the next growth phase

Biocon Q3FY26 results: Revenue up 9%, net profit rises on generics push

Board gives in-principle nod to make Biocon Biologics a wholly owned subsidiary as Q3 net profit climbs to Rs 143.8 crore

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,

Stocks to watch, Jan 22: Eternal, Dr Reddys, IndiGo, DLF, HPCL, PNB Housing

Stocks to watch on Thursday, January 22, 2026: KEI Industries, Bajaj Consumer Care, PNB Housing Finance and Jindal Stainless are among other key stocks to track today

Stocks to Watch today, Jan 16: RIL, Infosys, ICICI Pru AMC, Jio Financial

Stocks to watch on January 16, 2026: Stocks like Infosys, ICICI Prudential AMC, Biocon, Angel One and HDB Financial Services will remain in focus today

Biocon raises ₹4,150 crore via QIP issue on strong investor demand

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process. The initiative saw issuance of 1,12,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per share, the Bengaluru-based firm said in a regulatory filing. The QIP, which opened on January 12 and closed on January 14, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in the company's growth prospects, it added. The proceeds from the QIP will be primarily utilised to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Ltd, including repayment of debt availed in this regard, Biocon said. The company recently announced its board has approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris' stake, thereby making Biocon

Stocks to Watch today, Jan 13: TCS, HCL Tech, Anand Rathi Wealth, Biocon

Stocks to watch on January 13, 2026: Stocks like TCS, HCL Technologies, Anand Rathi Wealth, Biocon and NBCC will remain in focus today

Biocon opens ₹4,500 crore QIP, sets floor price at ₹387.74 per share

Biocon has opened a ₹4,500-crore QIP and fixed a floor price of ₹387.74 per share. The company said it may offer a discount of up to 5% and will finalise pricing with lead managers

Stocks to Watch today, Jan 7: Titan, Biocon, Godrej Con, Lodha, YES Bank

Stocks to Watch today, January 7, 2026: Godrej Consumer, Titan, Jubilant FoodWorks, YES Bank are among key stocks that will be in focus today

New Year picks 2026: Motilal Oswal Wealth bets on Airtel, SBI, Eternal

New Year picks 2026: Motilal Oswal Wealth Management has picked SBI, Airtel, Biocon, Eternal and others for the upcoming year; check details here

Ajanta Pharma signs pact with Biocon to sell semaglutide in 26 countries

Ajanta Pharma has signed an in-licensing pact with Biocon to market semaglutide across 26 countries in Africa, the Middle East and Central Asia, subject to approvals